272 studies found for:    "Expanded Access" [STUDY-TYPES]
Show Display Options
RSS Create an RSS feed from your search for:
"Expanded Access" [STUDY-TYPES]
Need help? See RSS Feeds
Choose a feed type:
Show studies that were first received in the last 14 daysShow studies that were first received in the last 14 days
Show studies added or modified in the last 14 daysShow studies that were added or modified in the last 14 days
Rank Status Study
1 Available Afatinib Expanded Access Program
Condition: Carcinoma, Non-Small-Cell Lung
Intervention: Drug: afatinib
2 Available Program for Pembrolizumab (MK-3475) in Participants With Metastatic Melanoma Who Have Failed Standard of Care Therapy Including Ipilimumab (MK-3475-030)
Condition: Melanoma
Intervention: Biological: Pembrolizumab
3 Approved for marketing Compassionate Use of Pennsaid Topical Lotion (Diclofenac) in Osteo or Rheumatoid Arthritis
Condition: Osteoarthritis of the Hand
Intervention: Drug: Diclofenac
4 Available Expanded Use of G-CSF Mobilized Donor CD34+ Selected Cells for Allogeneic Transplantation
Conditions: Chronic Myeloid Leukemia;   Myelodysplastic Syndrome;   Acute Myeloid Leukemia
Intervention: Biological: G-CSF mobilized CD34+ selected cells for transplantation
5 Approved for marketing Open Label Study to Assess Efficacy and Safety of the Fully Human Anti-TNF-Alpha Monoclonal Antibody Adalimumab
Condition: Rheumatoid Arthritis
Intervention: Biological: adalimumab
6 Unknown  131I-Labeled MIBG for Refractory Neuroblastoma: A Compassionate Use Protocol
Condition: Neuroblastoma
Intervention: Drug: Metaiodobenzylguanidine (MIBG)
7 Available Long-Term Compassionate Use Study for Continued Administration of SCB01A-01
Condition: Malignant Solid Tumour
Intervention: Drug: SCB01A
8 No longer available Duloxetine Compassionate Use in Patients Who Have Completed a Previous Neuroscience Duloxetine Clinical Trial
Conditions: Major Depressive Disorder;   Fibromyalgia;   Diabetic Peripheral Neuropathic Pain;   Generalized Anxiety Disorder
Intervention: Drug: Duloxetine Hydrochloride
9 Approved for marketing A Treatment-Option Study of Brentuximab Vedotin in Patients With Progression of Hodgkin Lymphoma or Systemic Anaplastic Large Cell Lymphoma
Conditions: Disease, Hodgkin;   Lymphoma, Large-Cell, Anaplastic;   Lymphoma, Non-Hodgkin
Intervention: Drug: brentuximab vedotin
10 Available Expanded Treatment Protocol With LDK378 in ALK(+) NSCLC
Condition: Non-small Cell Lung Cancer (NSCLC)
Intervention: Drug: LDK378
11 Unknown  Technology Platform and System Construction of Clinical Evaluation Studies on New Drugs of Hematological Malignancy
Condition: Multiple Myeloma
Intervention: Drug: Bortezomib/Dexamethasone/Melphalan
12 Approved for marketing A Phase III Second Line Trial in Advanced Pancreatic Cancer CONKO 003
Condition: Pancreatic Cancer
Intervention: Drug: OFF in experimental arm
13 Available Effect of Genes on Rosuvastatin Therapy for Hyperlipidemia
Condition: Hyperlipidemia
Interventions: Drug: rosuvastatin,fenofibrate;   Genetic: CYP2C9, UGT1A1, UGT1A3, OATP2, BCRP
14 Approved for marketing Humanitarian Device Exemption
Condition: Dystonia
Intervention: Device: Medtronic Activa Gpi
15 No longer available Request for Single Patient IND for Compassionate/Emergency Use of Tocilizumab
Condition: Juvenile Idiopathic Arthritis
Intervention: Drug: Tocilizumab
16 No longer available HEMOLEVEN® Expanded Access Program Prevention of Surgical/Postpartum Hemorrhage Severe Inherited Factor XI Deficiency
Conditions: Wound; Rupture, Surgery, Cesarean Section;   Postpartum Hemorrhage;   Surgery
Intervention: Biological: Hemoleven
17 Approved for marketing SynCardia Freedom Driver System Study
Condition: Biventricular Failure
Intervention: Device: CardioWest temporary Total Artificial Heart (TAH-t) System
18 Available Dextromethorphan Added on for the Patients With ADHD
Condition: Attention Deficit Hyperactivity Disorder
Intervention: Drug: Dextromethorphan
19 Approved for marketing Expanded Access Program of Ponatinib
Conditions: Chronic Myeloid Leukemia (CML);   Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL)
Intervention: Drug: ponatinib
20 Temporarily not available Use of Pan-Vascular Endothelial Growth Factor Receptor (Pan-VEGF) Blockade for the Treatment of Retinopathy of Prematurity (ROP) (Compassionate Use BLOCK-ROP)
Condition: Retinopathy of Prematurity
Intervention: Drug: Bevacizumab (Avastin)

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years